logo

Moleculin Biotech Inc (MBRX)



Trade MBRX now with
  Date
  Headline
5/8/2020 7:32:07 AM Moleculin To Adjourn 2020 Annual Meeting Of Stockholders To June 15, 2020
4/28/2020 7:38:51 AM Moleculin Biotech Now Authorized By URPL To Accelerate Phase 1 Dose Escalation Portion Of Clinical Trial Of Annamycin
4/28/2020 7:30:00 AM Moleculin Approved to Accelerate European Clinical Trial (Press Release)
4/8/2020 7:35:56 AM Moleculin Biotech Announces Active Compound In WP1122 Reduces Coronavirus Replication In Vitro By 100%
4/2/2020 7:31:56 AM Moleculin Announces Additional Positive Safety Data In EU AML Trial
3/20/2020 7:34:32 AM Moleculin Announces Patent Filing To Cover The Use Of WP1122 And Analogs As Therapies To Limit Ability Of Coronavirus
3/17/2020 7:32:52 AM Moleculin Biotech Enters Deal With UTMB To Conduct Research On Moleculin's Patented Portfolio Of Molecular Inhibitors
3/4/2020 7:30:00 AM Moleculin Issues Video Shareholder Letter (Press Release)
2/20/2020 7:51:07 AM Moleculin Reports Positive Independent Report Of No Cardiotoxicity In Annamycin Phase 1 To Date
2/18/2020 7:37:51 AM Moleculin Biotech Announces Final Data From CTCL Clinical Trial Of WP1220 For Cutaneous T-cell Lymphoma
2/5/2020 7:31:20 AM Moleculin To Seek Accelerated FDA Approval And Plans For Pivotal Phase 2 AML Trial
2/3/2020 7:36:08 AM Moleculin Biotech Unveils Successful Completion Of US Phase 1 AML Trial Of Annamycin
12/4/2019 7:32:15 AM Moleculin Announces Addl Positive Interim Results From Phase 1/2 Clinical Studies Of Annamycin In Acute Myeloid Leukemia